DE69830900D1 - Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen - Google Patents

Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen

Info

Publication number
DE69830900D1
DE69830900D1 DE69830900T DE69830900T DE69830900D1 DE 69830900 D1 DE69830900 D1 DE 69830900D1 DE 69830900 T DE69830900 T DE 69830900T DE 69830900 T DE69830900 T DE 69830900T DE 69830900 D1 DE69830900 D1 DE 69830900D1
Authority
DE
Germany
Prior art keywords
antigen
tolerance
compositions contain
immunological tolerance
binding compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69830900T
Other languages
English (en)
Other versions
DE69830900T2 (de
Inventor
Jacob Sten Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRIOTOL AB, VäSTRA FRöLUNDA, SE
Original Assignee
Jacob Sten Petersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacob Sten Petersen filed Critical Jacob Sten Petersen
Publication of DE69830900D1 publication Critical patent/DE69830900D1/de
Application granted granted Critical
Publication of DE69830900T2 publication Critical patent/DE69830900T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69830900T 1997-04-23 1998-04-23 Immunologische toleranz-induzierende zusammensetzungen enthaltend antigen und mucosabindungskomponente Expired - Lifetime DE69830900T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4418297P 1997-04-23 1997-04-23
US4418497P 1997-04-23 1997-04-23
US44182P 1997-04-23
US44184P 1997-04-23
PCT/US1998/008361 WO1998047529A1 (en) 1997-04-23 1998-04-23 Combinations of antigen and mucosal binding component for inducing specific immunological tolerance

Publications (2)

Publication Number Publication Date
DE69830900D1 true DE69830900D1 (de) 2005-08-25
DE69830900T2 DE69830900T2 (de) 2006-05-24

Family

ID=26721263

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830900T Expired - Lifetime DE69830900T2 (de) 1997-04-23 1998-04-23 Immunologische toleranz-induzierende zusammensetzungen enthaltend antigen und mucosabindungskomponente

Country Status (8)

Country Link
US (1) US7097845B2 (de)
EP (1) EP0977586B1 (de)
JP (1) JP2001523249A (de)
AT (1) ATE299711T1 (de)
AU (1) AU7161098A (de)
DE (1) DE69830900T2 (de)
DK (1) DK0977586T3 (de)
WO (1) WO1998047529A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800487D0 (en) 1998-01-09 1998-03-04 Oratol Limited Therapies
AU7404800A (en) * 1999-09-30 2001-04-30 Novo Nordisk A/S A method for preparing conjugates between an antigen and mucosal binding component
WO2001054722A1 (en) 2000-01-25 2001-08-02 Board Of Regents Of The University Of Nebraska Pre-transplant accommodated organs resistant to anti-donor immunity
US7897575B2 (en) * 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
JP4339598B2 (ja) * 2001-05-23 2009-10-07 デュオトール アーベー 毒素サブユニットまたはそのフラグメントと共に、又はこれとコンジュゲートされたアレルゲンの経皮投与によるアレルギー反応の抑制
EP1660531A2 (de) 2003-08-05 2006-05-31 Novo Nordisk A/S Neue insulinderivate
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
CN107029212A (zh) * 2010-05-10 2017-08-11 诺沃—诺迪斯克有限公司 用于制备胰岛素‑锌复合物的方法
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
TW202245842A (zh) * 2021-02-16 2022-12-01 美商應用分子運輸公司 具鋅之固體口服組合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666837A (en) 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
EP0194794A3 (de) * 1985-03-08 1986-12-17 Takeda Chemical Industries, Ltd. Saccharid-Verdauung hemmende Zusammensetzung
CA1336954C (en) 1987-06-24 1995-09-12 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
JPH02235823A (ja) 1989-03-09 1990-09-18 Watanabe Mitsuko 抗アレルギー剤
JP2891485B2 (ja) 1989-09-25 1999-05-17 科学技術振興事業団 移植拒絶反応抑制剤
HUT61487A (en) 1989-12-20 1993-01-28 Brigham & Womens Hospital Process for producing aerosol pharmaceutical composition comprising autoantigens
ES2107459T3 (es) 1990-03-02 1997-12-01 Autoimmune Inc Mejora de la regulacion represora de enfermedades autoinmunes por administracion oral o enteral de autoantigenos.
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
JP3198390B2 (ja) * 1990-09-03 2001-08-13 武田薬品工業株式会社 経粘膜用製剤
IL99864A (en) 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
EP0627933B1 (de) 1992-02-28 2002-11-27 Autoimmune, Inc. Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
US5453272A (en) 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
JP3109328B2 (ja) 1993-05-19 2000-11-13 ウシオ電機株式会社 加熱定着装置
NZ266739A (en) 1993-06-02 1997-07-27 Tvw Telethon Inst Child Health Inducing immunologic tolerance by administering a cryptic peptide derived from the antigen der pi
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
JP2847696B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
JP2847695B2 (ja) * 1994-05-11 1999-01-20 田辺製薬株式会社 血糖降下剤
IL111866A (en) 1994-12-04 2005-03-20 Yeda Res & Dev Pharmaceutical compositions comprising the b-oligomer of pertussis toxin
MX9705198A (es) 1995-01-10 1997-12-31 Fibrogen Inc Metodos y formulaciones a base de colagena para el tratamiento de enfermedades mediadas por el sistema inmune.
AU6113896A (en) 1995-06-05 1996-12-24 Brigham And Women's Hospital Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents

Also Published As

Publication number Publication date
WO1998047529A1 (en) 1998-10-29
DK0977586T3 (da) 2005-12-05
EP0977586A1 (de) 2000-02-09
US20020119159A1 (en) 2002-08-29
EP0977586B1 (de) 2005-07-20
AU7161098A (en) 1998-11-13
US7097845B2 (en) 2006-08-29
DE69830900T2 (de) 2006-05-24
ATE299711T1 (de) 2005-08-15
JP2001523249A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
DE69830900D1 (de) Immunologische toleranz induzierende zusammensetzungen enthaltend antigen und mukosale bindende verbindungen
MX9301716A (es) Una composicion farmaceutica que tiene un sistema definido de lipidos.
FI972945A0 (fi) Antigeenien antamiseen soveltuvia koostumuksia
BG99261A (en) Steroid glycosides for the treatment of hyperchlesterolemia
ATE356608T1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
MX9203396A (es) Monohidrato de furoato de mometasona, proceso para producirlo y composiciones farmaceuticas.
NZ306653A (en) Isolated dna il-17 receptors
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
TR200101822T2 (tr) Kontrollü salınan galantamin bileşimi
ES2189966T3 (es) Composiciones adhesivas de cianoacrilato para unir vidrio.
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
DK0588578T3 (da) Immunogener
WO1998046270A3 (en) Polymeric conjugates polyvalently presenting an agent for therapy
DK0789590T3 (da) Chitosaninduceret immunforstærkning
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
DK0712311T3 (da) Antiglucocorticoidsteroider til behandling af angstlidelser
DK0584247T3 (da) Sammensætninger til behandling af kronisk træthedssyndrom
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
ATE305311T1 (de) Zusammensetzung zur behandlung von herzinsuffizienz
DK0972521T3 (da) Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer
ATE141248T1 (de) Neue bis-phenyl-hexene
CA2255867A1 (en) Chitosan induced immunopotentiation
ATE315398T1 (de) Synergistische, gold und ein corticosteroid enthaltende zusammensetzungen.
AU5662996A (en) Compounds and compositions for delivering active agents
IT1162825B (it) Composizioni per il trattamento di infezioni da virus erpetico

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TRIOTOL AB, VäSTRA FRöLUNDA, SE

8364 No opposition during term of opposition